-
Novelion Therapeutics Announces US Court Confirmation of Aegerion Bankruptcy Case, Update on Nasdaq Delisting and Date of Annual General Meeting of Shareholders
-
Novelion Therapeutics Provides Update Regarding Delisting from Nasdaq and Aegerion Bankruptcy Case
-
Novelion Therapeutics Provides Update Regarding Delisting from Nasdaq and Aegerion Bankruptcy Case
-
Novelion Therapeutics Announces Issuance of General Cease Trade Order in Canada and Notice of Delisting from Nasdaq
-
Novelion Therapeutics Announces Issuance of General Cease Trade Order in Canada and Notice of Delisting from Nasdaq
-
Novelion Therapeutics Announces Anticipated Late Filing of Quarterly Report on Form 10-Q for the Quarter Ended June 30, 2019
-
Novelion Therapeutics Announces Anticipated Late Filing of Quarterly Report on Form 10-Q for the Quarter Ended June 30, 2019
-
Novelion Therapeutics Announces Dismissal of Whitefort Capital Petition
-
Novelion Therapeutics Announces Dismissal of Whitefort Capital Petition
-
Novelion Therapeutics (NVLN) Receives Delisting Notifications from Nasdaq
-
Novelion Therapeutics Receives Delisting Notifications
-
Novelion Therapeutics Receives Delisting Notifications
-
Novelion Therapeutics (NVLN) Releases Statement Responding to Whitefort Capital Petition
-
Novelion Therapeutics Responds to Whitefort Capital Petition
-
Novelion Therapeutics Responds to Whitefort Capital Petition
-
Novelion Therapeutics (NVLN) Unit Aegerion to Recapitalize Through Court Supervised Process
-
Novelion Therapeutics Announces Subsidiary Aegerion Pharmaceuticals to Recapitalize Through Court Supervised Process In Which Amryt Pharma Plc Will Acquire 100% of Reorganized Stock of Aegerion
-
Novelion Therapeutics Announces Subsidiary Aegerion Pharmaceuticals to Recapitalize Through Court Supervised Process In Which Amryt Pharma Plc Will Acquire 100% of Reorganized Stock of Aegerion
-
Novelion Therapeutics Reports First Quarter 2019 Financial Results
-
Novelion Therapeutics Reports First Quarter 2019 Financial Results
-
Novelion Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
-
Novelion Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
-
Novelion Therapeutics (NVLN) Subsidiary Aegerion Pharmaceuticals, Inc. Signs Licensing Agreement with Recordati Rare Diseases Inc. for JUXTAPID in Japan
-
Novelion Therapeutics Subsidiary Enters Into Licensing Agreement for JUXTAPID® in Japan
-
Novelion Therapeutics Subsidiary Enters Into Licensing Agreement for JUXTAPID® in Japan
-
Novelion Therapeutics Announces Leadership Change
-
Novelion Therapeutics Announces Leadership Change
-
Novelion Therapeutics Reports Third Quarter 2018 Financial Results
-
Novelion Therapeutics Reports Third Quarter 2018 Financial Results
-
Novelion Therapeutics Subsidiary Enters Into Term Loan Agreement and Novelion Provides Business Update
-
Novelion Therapeutics Subsidiary Enters Into Term Loan Agreement and Novelion Provides Business Update

